Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
IL-10 provides cardioprotection in diabetic myocardial infarction via upregulation of Heme clearance pathways
Rajesh Gupta, … , Jiang Tian, Raj Kishore
Rajesh Gupta, … , Jiang Tian, Raj Kishore
Published September 3, 2020
Citation Information: JCI Insight. 2020;5(17):e133050. https://doi.org/10.1172/jci.insight.133050.
View: Text | PDF
Research Article Cardiology Therapeutics

IL-10 provides cardioprotection in diabetic myocardial infarction via upregulation of Heme clearance pathways

  • Text
  • PDF
Abstract

Diabetes is a risk factor for myocardial infarction, and outcomes after myocardial infarction are worse among diabetics compared with nondiabetics. Diabetes is associated with impaired Heme clearance. Here, we determined whether heme toxicity and impaired heme clearance contribute to diabetic myocardial infarction injury and assessed IL-10 as a therapeutic agent for diabetic myocardial infarction. Plasma-free hemoglobin was significantly elevated in diabetic mice compared with nondiabetic mice after myocardial infarction. Infarct size had strong correlation to the level of plasma-free hemoglobin. Hemoglobin and reactive iron deposition within the infarct zone were also demonstrated in diabetic MI. IL-10 significantly reduced infarct size and improved cardiac function in diabetic mice. Moreover, IL-10 improved capillary density, reduced apoptosis, and decreased inflammation in the border zone of the infarcted hearts, findings that were partially inhibited by Tin protoporphyrin (a heme oxygenase-1 inhibitor). IL-10 upregulated CD163, the hemoglobin:haptoglobin scavenger receptor, and heme oxygenase-1 in THP-1–derived and primary human CD14+ macrophages. IL-10 significantly protected against ischemic injury when HL-1 cardiomyocytes were cotreated with hemoglobin. Together, our findings indicate that IL-10 is cardioprotective in diabetic myocardial infarction via upregulation of heme clearance pathways. These findings implicate heme clearance as a potentially novel therapeutic direction for diabetic myocardial infarction.

Authors

Rajesh Gupta, Lijun Liu, Xiaolu Zhang, Xiaoming Fan, Prasanna Krishnamurthy, Suresh Verma, Jörn Tongers, Sol Misener, Nikita Ashcherkin, Hongliu Sun, Jiang Tian, Raj Kishore

×

Figure 3

Systemic IL-10 induced HO-1 expression in the infarcted hearts in diabetic mice.

Options: View larger image (or click on image) Download as PowerPoint
Systemic IL-10 induced HO-1 expression in the infarcted hearts in diabet...
Diabetic mouse left ventricular tissues on day 3 after MI, including the infarct and border zone, were lysed and measured for HO-1 protein expression by Western blot. GAPDH was used as a loading control. (A) Representative blots of HO-1 and GAPDH. (B) Quantitative analysis of HO-1 expression in diabetic hearts after MI. One-way ANOVA followed by Tukey’s test. n = 3 per group, *P < 0.05 vs. sham. (C) Left: immunofluorescence staining of HO-1 (green fluorescence) in the border zones of heart sections on day 3 after MI in control and diabetic mice. Blue color is the DAPI staining. Scale bar: 50 μm. Right: quantitative data of HO-1+ cells on day 3 after MI for control and diabetic mouse hearts. Independent t test. n = 9, *P < 0.05 vs. Con MI.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts